{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:49:01Z","timestamp":1775713741844,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Cholesterol dysregulation plays a central role in tumor progression and has emerged as a potential therapeutic target. Its dysregulation within the tumor microenvironment is increasingly considered a strong modifier of multiple cancer traits. Targeting cholesterol, particularly its biosynthetic pathway, has been explored to enhance therapy, yet outcomes remain inconsistent, likely reflecting a tumor-specific reprogramming of cholesterol metabolism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>TCGA and GTEx transcriptomic data from 11,735 samples was analyzed to conduct an integrative assessment of key cholesterol-related processes\u2014biosynthesis, uptake, storage, efflux, and catabolism\u2014across 26 cancer types.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Cholesterol metabolism dysregulation was highly heterogeneous among tumors, affecting different metabolic pathways, the magnitude of those differences and the direction relative to normal tissue. Notably, we identified cholesterol uptake as the most consistently altered pathway across tumors, positively correlated with tumor aggressiveness and poorer patient survival. Uptake correlated positively with inflammatory pathways (e.g.,\n                      <jats:italic>Complement System<\/jats:italic>\n                      and\n                      <jats:italic>IL-6-JAK-STAT3 Signaling<\/jats:italic>\n                      ) and with immune microenvironment features, including Tregs, cytotoxic and CD4\n                      <jats:sup>+<\/jats:sup>\n                      \u2009T cells, eosinophils, endothelial cells, as well as elevated expression of immune checkpoints. Cholesterol uptake also correlated with enhanced KRAS signaling. Particularly,\n                      <jats:italic>KRAS<\/jats:italic>\n                      mutations were more frequent in tumors with high uptake scores, and those patients had the worst overall survival. Nonetheless, high uptake tumors lacking\n                      <jats:italic>KRAS<\/jats:italic>\n                      mutations had higher KRAS signaling scores than\n                      <jats:italic>KRAS<\/jats:italic>\n                      -mutant tumors with low uptake, highlighting a central role of cholesterol uptake on the regulation of KRAS signaling.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In summary, cholesterol uptake emerges as a conserved driver of tumor aggressiveness and a promising therapeutic target to synergize with immunotherapy and KRAS inhibition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s13402-026-01171-z","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:35:37Z","timestamp":1770888937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pan-cancer analysis of cholesterol metabolism reveals the uptake as a modulator of tumor immune features and of the KRAS pathway"],"prefix":"10.1007","volume":"49","author":[{"given":"Ana Lu\u00edsa","family":"Machado","sequence":"first","affiliation":[]},{"given":"Ana","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Ver\u00f3nica","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Lu\u00edsa","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Jessica","family":"Roelands","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"N. F. C. C.","family":"Miranda","sequence":"additional","affiliation":[]},{"given":"Maria Jos\u00e9","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"S\u00e9rgia","family":"Velho","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"1","key":"1171_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41392-022-01125-5","volume":"7","author":"Y Duan","year":"2022","unstructured":"Y. Duan, K. Gong, S. Xu, F. Zhang, X. Meng, J. Han, Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal. Transduct. Target. Therapy. 7(1), 265 (2022)","journal-title":"Signal. Transduct. Target. Therapy"},{"issue":"1","key":"1171_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40170-023-00315-1","volume":"11","author":"SS Mayengbam","year":"2023","unstructured":"S.S. Mayengbam, A. Singh, H. Yaduvanshi, F.K. Bhati, B. Deshmukh, D. Athavale et al., Cholesterol reprograms glucose and lipid metabolism to promote proliferation in colon cancer cells. Cancer Metabolism. 11(1), 15 (2023)","journal-title":"Cancer Metabolism"},{"issue":"24","key":"1171_CR3","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.3390\/cancers13246165","volume":"13","author":"L Shimolina","year":"2021","unstructured":"L. Shimolina, A. Gulin, N. Ignatova, I. Druzhkova, M. Gubina, M. Lukina et al., The role of plasma membrane viscosity in the response and resistance of cancer cells to oxaliplatin. Cancers. 13(24), 6165 (2021)","journal-title":"Cancers"},{"issue":"3","key":"1171_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3109\/07853890008998823","volume":"32","author":"S Bellosta","year":"2000","unstructured":"S. Bellosta, N. Fed, F. Bernini, R. Paoletti, A. Corsini, Non-lipid-related effects of Statins. Ann. Med. 32(3), 164\u2013176 (2000)","journal-title":"Ann. Med."},{"issue":"1","key":"1171_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12935-023-02884-z","volume":"23","author":"M Tsubaki","year":"2023","unstructured":"M. Tsubaki, T. Takeda, T. Matsuda, K. Kishimoto, H. Takefuji, Y. Taniwaki et al., Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy. Cancer Cell Int. 23(1), 73 (2023)","journal-title":"Cancer Cell Int."},{"issue":"3","key":"1171_CR6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s10549-009-0594-8","volume":"122","author":"CJ Antalis","year":"2010","unstructured":"C.J. Antalis, T. Arnold, T. Rasool, B. Lee, K.K. Buhman, R.A. Siddiqui, High ACAT1 expression in Estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation. Breast Cancer Res. Treat. 122(3), 661\u2013670 (2010)","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"1171_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.gene.2016.04.029","volume":"587","author":"L Chushi","year":"2016","unstructured":"L. Chushi, W. Wei, X. Kangkang, F. Yongzeng, X. Ning, C. Xiaolei, HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells. Gene. 587(1), 42\u201347 (2016)","journal-title":"Gene"},{"issue":"4","key":"1171_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/pros.22758","volume":"74","author":"P Saraon","year":"2014","unstructured":"P. Saraon, D. Trudel, K. Kron, A. Dmitromanolakis, J. Trachtenberg, B. Bapat et al., Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression. Prostate. 74(4), 372\u2013380 (2014)","journal-title":"Prostate"},{"key":"1171_CR9","doi-asserted-by":"publisher","first-page":"622908","DOI":"10.3389\/fcell.2021.622908","volume":"9","author":"R Vona","year":"2021","unstructured":"R. Vona, E. Iessi, P. Matarrese, Role of cholesterol and lipid rafts in cancer signaling: a promising therapeutic opportunity? Front. cell. Dev. Biology. 9, 622908 (2021)","journal-title":"Front. cell. Dev. Biology"},{"issue":"4","key":"1171_CR10","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1172\/JCI96313","volume":"129","author":"T Gruosso","year":"2019","unstructured":"T. Gruosso, M. Gigoux, V.S.K. Manem, N. Bertos, D. Zuo, I. Perlitch et al., Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J. Clin. Investig. 129(4), 1785\u20131800 (2019)","journal-title":"J. Clin. Investig."},{"issue":"1","key":"1171_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","volume":"30","author":"X Ma","year":"2019","unstructured":"X. Ma, E. Bi, Y. Lu, P. Su, C. Huang, L. Liu et al., Cholesterol induces CD8\u2009+\u2009T cell exhaustion in the tumor microenvironment. Cell Metabol. 30(1), 143\u2013156 (2019). e5","journal-title":"Cell Metabol."},{"issue":"12","key":"1171_CR12","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.18632\/oncotarget.1376","volume":"4","author":"E Mira","year":"2013","unstructured":"E. Mira, L. Carmona-Rodr\u00edguez, M. Tard\u00e1guila, I. Azcoitia, A. Gonz\u00e1lez-Mart\u00edn, L. Almonacid et al., A lovastatin-elicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumors. Oncotarget. 4(12), 2288 (2013)","journal-title":"Oncotarget"},{"key":"1171_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.phrs.2014.06.013","volume":"88","author":"S Pisanti","year":"2014","unstructured":"S. Pisanti, P. Picardi, E. Ciaglia, A. D\u2019Alessandro, M. Bifulco, Novel prospects of Statins as therapeutic agents in cancer. Pharmacol. Res. 88, 84\u201398 (2014)","journal-title":"Pharmacol. Res."},{"issue":"1","key":"1171_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nm.2074","volume":"16","author":"EJ Villablanca","year":"2010","unstructured":"E.J. Villablanca, L. Raccosta, D. Zhou, R. Fontana, D. Maggioni, A. Negro et al., Tumor-mediated liver X receptor-\u03b1 activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat. Med. 16(1), 98\u2013105 (2010)","journal-title":"Nat. Med."},{"key":"1171_CR15","doi-asserted-by":"publisher","first-page":"1234713","DOI":"10.3389\/fonc.2023.1234713","volume":"13","author":"Q Zhou","year":"2023","unstructured":"Q. Zhou, Z. Jiao, Y. Liu, P.N. Devreotes, Z. Zhang, The effects of Statins in patients with advanced-stage cancers-a systematic review and meta-analysis. Front. Oncol. 13, 1234713 (2023)","journal-title":"Front. Oncol."},{"issue":"7","key":"1171_CR16","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1054\/bjoc.2000.1716","volume":"84","author":"S Kawata","year":"2001","unstructured":"S. Kawata, E. Yamasaki, T. Nagase, Y. Inui, N. Ito, Y. Matsuda et al., Effect of Pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer. 84(7), 886\u2013891 (2001)","journal-title":"Br. J. Cancer"},{"issue":"1","key":"1171_CR17","first-page":"9125238","volume":"2016","author":"H-Y Chen","year":"2016","unstructured":"H.-Y. Chen, Q. Wang, Q.-H. Xu, L. Yan, X.-F. Gao, Y.-H. Lu et al., Statin as a combined therapy for advanced-stage ovarian cancer: a propensity score matched analysis. Biomed. Res. Int. 2016(1), 9125238 (2016)","journal-title":"Biomed. Res. Int."},{"issue":"24","key":"1171_CR18","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1093\/jnci\/djj499","volume":"98","author":"EA Platz","year":"2006","unstructured":"E.A. Platz, M.F. Leitzmann, K. Visvanathan, E.B. Rimm, M.J. Stampfer, W.C. Willett et al., Statin drugs and risk of advanced prostate cancer. J. Natl Cancer Inst. 98(24), 1819\u20131825 (2006)","journal-title":"J. Natl Cancer Inst."},{"issue":"8","key":"1171_CR19","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1158\/0008-5472.CAN-15-2613","volume":"76","author":"OF Kuzu","year":"2016","unstructured":"O.F. Kuzu, M.A. Noory, G.P. Robertson, The role of cholesterol in cancer. Cancer Res. 76(8), 2063\u20132070 (2016)","journal-title":"Cancer Res."},{"issue":"12","key":"1171_CR20","doi-asserted-by":"publisher","first-page":"e28813","DOI":"10.1371\/journal.pone.0028813","volume":"6","author":"DG Menter","year":"2011","unstructured":"D.G. Menter, V.P. Ramsauer, S. Harirforoosh, K. Chakraborty, P. Yang, L. Hsi et al., Differential effects of Pravastatin and Simvastatin on the growth of tumor cells from different organ sites. PloS One. 6(12), e28813 (2011)","journal-title":"PloS One"},{"issue":"1","key":"1171_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.stem.2023.11.011","volume":"31","author":"X Duan","year":"2024","unstructured":"X. Duan, T. Zhang, L. Feng, de N. Silva, B. Greenspun, X. Wang et al., A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS. Cell. Stem Cell. 31(1), 71\u201388 (2024). e8","journal-title":"Cell. Stem Cell."},{"issue":"5","key":"1171_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"E. Cerami, J. Gao, U. Dogrusoz, B.E. Gross, S.O. Sumer, B.A. Aksoy et al., The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2(5), 401\u2013404 (2012)","journal-title":"Cancer Discov."},{"issue":"269","key":"1171_CR23","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"J. Gao, B.A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S.O. Sumer et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6(269), pl1\u2013pl (2013)","journal-title":"Sci. Signal."},{"issue":"7269","key":"1171_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"D.A. Barbie, P. Tamayo, J.S. Boehm, S.Y. Kim, S.E. Moody, I.F. Dunn et al., Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 462(7269), 108\u2013112 (2009)","journal-title":"Nature"},{"key":"1171_CR25","doi-asserted-by":"crossref","unstructured":"G. Korotkevich, V. Sukhov, N. Budin, B. Shpak, M.N. Artyomov, A. Sergushichev, Fast Gene Set Enrich. Anal. Biorxiv, 060012 (2016)","DOI":"10.1101\/060012"},{"issue":"1","key":"1171_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1158\/0008-5472.CAN-17-2084","volume":"78","author":"P Dias Carvalho","year":"2018","unstructured":"P. Dias Carvalho, C.F. Guimaraes, A.P. Cardoso, S. Mendonca, A.M. Costa, M.J. Oliveira et al., KRAS oncogenic signaling extends beyond cancer cells to orchestrate the microenvironment. Cancer Res. 78(1), 7\u201314 (2018)","journal-title":"Cancer Res."},{"issue":"1","key":"1171_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-024-02218-1","volume":"24","author":"Q Ma","year":"2025","unstructured":"Q. Ma, W. Zhang, K. Wu, L. Shi, The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy. Mol. Cancer. 24(1), 14 (2025)","journal-title":"Mol. Cancer"},{"issue":"1","key":"1171_CR28","doi-asserted-by":"publisher","first-page":"5961","DOI":"10.1038\/s41467-021-26213-y","volume":"12","author":"G Mendiratta","year":"2021","unstructured":"G. Mendiratta, E. Ke, M. Aziz, D. Liarakos, M. Tong, E.C. Stites, Cancer gene mutation frequencies for the US population. Nat. Commun. 12(1), 5961 (2021)","journal-title":"Nat. Commun."},{"key":"1171_CR29","doi-asserted-by":"publisher","first-page":"928821","DOI":"10.3389\/fphar.2023.928821","volume":"14","author":"W Xia","year":"2023","unstructured":"W. Xia, H. Wang, X. Zhou, Y. Wang, L. Xue, B. Cao et al., The role of cholesterol metabolism in tumor therapy, from bench to bed. Front. Pharmacol. 14, 928821 (2023)","journal-title":"Front. Pharmacol."},{"issue":"5","key":"1171_CR30","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ccell.2016.09.008","volume":"30","author":"GR Villa","year":"2016","unstructured":"G.R. Villa, J.J. Hulce, C. Zanca, J. Bi, S. Ikegami, G.L. Cahill et al., An LXR-cholesterol axis creates a metabolic co-dependency for brain cancers. Cancer cell. 30(5), 683\u2013693 (2016)","journal-title":"Cancer cell."},{"issue":"12","key":"1171_CR31","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1158\/2159-8290.CD-21-0211","volume":"11","author":"R Riscal","year":"2021","unstructured":"R. Riscal, C.J. Bull, C. Mesaros, J.M. Finan, M. Carens, E.S. Ho et al., Cholesterol auxotrophy as a targetable vulnerability in clear cell renal cell carcinoma. Cancer Discov. 11(12), 3106\u20133125 (2021)","journal-title":"Cancer Discov."},{"issue":"2","key":"1171_CR32","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s44321-023-00015-9","volume":"16","author":"Y Bai","year":"2024","unstructured":"Y. Bai, T. Li, Q. Wang, W. You, H. Yang, X. Xu et al., Shaping immune landscape of colorectal cancer by cholesterol metabolites. EMBO Mol. Med. 16(2), 334\u2013360 (2024)","journal-title":"EMBO Mol. Med."},{"key":"1171_CR33","doi-asserted-by":"crossref","unstructured":"M. Wu, X. Zhou, X. Zhou, G. Wang, Y. Zeng, J. Li et al., ZDHHC3-mediated SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape in hepatocellular carcinoma. Cell. Rep. 43(11) (2024)","DOI":"10.1016\/j.celrep.2024.114962"},{"issue":"1","key":"1171_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"H. Zhao, L. Wu, G. Yan, Y. Chen, M. Zhou, Y. Wu et al., Inflammation and tumor progression: signaling pathways and targeted intervention. Signal. Transduct. Target. Therapy. 6(1), 263 (2021)","journal-title":"Signal. Transduct. Target. Therapy"},{"key":"1171_CR35","doi-asserted-by":"crossref","unstructured":"La A. Cava, G. Castaldo, Cholesterol, inflammation and immunity. Frontiers 1696770 (2025)","DOI":"10.3389\/fimmu.2025.1696770"},{"issue":"10","key":"1171_CR36","doi-asserted-by":"publisher","first-page":"e0186649","DOI":"10.1371\/journal.pone.0186649","volume":"12","author":"SL Gonias","year":"2017","unstructured":"S.L. Gonias, N. Karimi-Mostowfi, S.S. Murray, E. Mantuano, A.S. Gilder, Expression of LDL receptor-related proteins (LRPs) in common solid malignancies correlates with patient survival. PloS One. 12(10), e0186649 (2017)","journal-title":"PloS One"},{"issue":"10","key":"1171_CR37","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/onc.2015.179","volume":"35","author":"SJ Ricoult","year":"2016","unstructured":"S.J. Ricoult, J.L. Yecies, I. Ben-Sahra, B.D. Manning, Oncogenic PI3K and K-Ras stimulate de Novo lipid synthesis through mTORC1 and SREBP. Oncogene. 35(10), 1250\u20131260 (2016)","journal-title":"Oncogene"},{"key":"1171_CR38","doi-asserted-by":"crossref","unstructured":"C. Zhang, R. Yu, S. Li, M. Yuan, T. Hu, J. Liu et al., KRAS mutation increases histone H3 lysine 9 lactylation (H3K9la) to promote colorectal cancer progression by facilitating cholesterol transporter GRAMD1A expression. Cell. Death Differ, 1\u201314 (2025)","DOI":"10.1038\/s41418-025-01533-4"},{"issue":"6","key":"1171_CR39","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.stem.2023.05.005","volume":"30","author":"E Guilbaud","year":"2023","unstructured":"E. Guilbaud, T. Barouillet, M. Ilie, C. Borowczyk, S. Ivanov, V. Sarrazy et al., Cholesterol efflux pathways hinder KRAS-driven lung tumor progenitor cell expansion. Cell. Stem Cell. 30(6), 800\u2013817 (2023). e9","journal-title":"Cell. Stem Cell."},{"issue":"33","key":"1171_CR40","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1038\/s41388-023-02771-x","volume":"42","author":"A Skorda","year":"2023","unstructured":"A. Skorda, A.R. Lauridsen, C. Wu, J. Huang, M. Mrackova, N.I. Winther et al., Activation of invasion by oncogenic reprogramming of cholesterol metabolism via increased NPC1 expression and macropinocytosis. Oncogene. 42(33), 2495\u20132506 (2023)","journal-title":"Oncogene"},{"issue":"1","key":"1171_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21541248.2016.1259710","volume":"10","author":"AH Grossmann","year":"2019","unstructured":"A.H. Grossmann, H. Zhao, N. Jenkins, W. Zhu, J.R. Richards, J.H. Yoo et al., The small GTPase ARF6 regulates protein trafficking to control cellular function during development and in disease. Small GTPases. 10(1), 1\u201312 (2019)","journal-title":"Small GTPases"},{"issue":"8","key":"1171_CR42","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrm3151","volume":"12","author":"HT McMahon","year":"2011","unstructured":"H.T. McMahon, E. Boucrot, Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat. Rev. Mol. Cell Biol. 12(8), 517\u2013533 (2011)","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"1171_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/10084","volume":"1","author":"T Kobayashi","year":"1999","unstructured":"T. Kobayashi, M.-H. Beuchat, M. Lindsay, S. Frias, R.D. Palmiter, H. Sakuraba et al., Late endosomal membranes rich in lysobisphosphatidic acid regulate cholesterol transport. Nat. Cell Biol. 1(2), 113\u2013118 (1999)","journal-title":"Nat. Cell Biol."},{"issue":"11","key":"1171_CR44","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/membranes10110364","volume":"10","author":"H Lu","year":"2020","unstructured":"H. Lu, J. Mart\u00ed, Influence of cholesterol on the orientation of the farnesylated GTP-bound KRas-4B binding with anionic model membranes. Membranes. 10(11), 364 (2020)","journal-title":"Membranes"},{"key":"1171_CR45","doi-asserted-by":"crossref","unstructured":"F. Guillaumond, G. Bidaut, M. Ouaissi, S. Servais, V. Gouirand, O. Olivares et al., Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proc. Natl. Acad. Sci. U.S.A.. 112(8), 2473\u20138 (2015)","DOI":"10.1073\/pnas.1421601112"},{"issue":"1","key":"1171_CR46","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1038\/s41467-022-31663-z","volume":"13","author":"CC Wong","year":"2022","unstructured":"C.C. Wong, J.-L. Wu, F. Ji, W. Kang, X. Bian, H. Chen et al., The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC\/KRAS-mutant colorectal cancer. Nat. Commun. 13(1), 3971 (2022)","journal-title":"Nat. Commun."}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01171-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-026-01171-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01171-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:03:56Z","timestamp":1770894236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-026-01171-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["1171"],"URL":"https:\/\/doi.org\/10.1007\/s13402-026-01171-z","relation":{},"ISSN":["2211-3436"],"issn-type":[{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}